NICE backs some K-Ras diagnostics, wants more data for others

The U.K.'s NICE issued K-Ras (KRAS) mutation status in adults with metastatic colorectal cancer (mCRC). The committee backed use of therascreen KRAS RGQ PCR Kit from Qiagen N.V. (Xetra:QIA; NASDAQ:QGEN) and KRAS LightMix Kit from Tib Molbiol GmbH (Berlin, Germany). Both tests have CE Mark approval.

NICE said there was insufficient evidence to make recommendations and requested additional data for five other tests, including Qiagen's therascreen KRAS Pyro Kit, KRAS StripAssay from ViennaLab Diagnostics GmbH (Vienna, Austria) and cobas KRAS Mutation Test from Roche (SIX:ROG; OTCQX:RHHBY). Comments on the draft guidance are due Oct. 24. ...